Skip to main content
. 2013 Apr;26(2):274–288. doi: 10.1128/CMR.00092-12

Fig 4.

Fig 4

Application of PK/PD modeling and simulation to integrate in vitro and in vivo data and guide drug and dosage selection. Dosage recommendations are further supported by determination of inflection points (a and b) in the MIC distribution obtained from clinical surveillance data and estimates of target drug exposure. (Adapted from reference 160 [Fig. 12.5] with kind permission from Springer Science+Business Media B.V.)